Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Prime-Boost Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Adults
2008-005133-30Phase 2Completed
- Sponsor
- Baxter International Inc.
- Start
- Dec 2008
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inactivated Vero cell based whole virus influenza A/H5N1 in avian influenza (HPAI), sponsored by Baxter International Inc. Primary endpoints: Immunogenicity and Safety. Started Dec 2008; status: completed.
02
Drugs
inactivated Vero cell based whole virus influenza A/H5N1
03
Conditions
avian influenza (HPAI)
Beyond the preview
Go deeper on 2008-005133-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005133-30.